Compare Stocks: MKKGY, CHGCY, TAK, and BAYRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$12.64 -0.7%	$14.01	$7.48 ▼ $15.23	$50.03B	0.57	403,832 shs	669,154 shs
CHGCY Chugai Pharmaceutical	$19.08 -1.3%	$21.30	$19.00 ▼ $34.84	$63.62B	0.6	280,012 shs	794,244 shs
MKKGY Merck KGaA	$30.87 +2.5%	$31.79	$23.73 ▼ $34.19	$19.46B	0.95	136,325 shs	105,355 shs
TAK Takeda Pharmaceutical	$17.87 +0.0%	$18.06	$12.99 ▼ $19.10	$57.23B	-0.07	2.23 million shs	2.05 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	-5.70%	-9.84%	-9.84%	-16.17%	+46.32%
CHGCY Chugai Pharmaceutical	-1.23%	-7.95%	-10.01%	-17.29%	-16.32%
MKKGY Merck KGaA	-3.18%	-1.68%	-6.84%	-10.76%	+6.24%
TAK Takeda Pharmaceutical	-1.79%	-3.91%	-1.95%	+6.81%	+21.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$12.64 -0.7%	$14.01	$7.48 ▼ $15.23	$50.03B	0.57	403,832 shs	669,154 shs
CHGCY Chugai Pharmaceutical	$19.08 -1.3%	$21.30	$19.00 ▼ $34.84	$63.62B	0.6	280,012 shs	794,244 shs
MKKGY Merck KGaA	$30.87 +2.5%	$31.79	$23.73 ▼ $34.19	$19.46B	0.95	136,325 shs	105,355 shs
TAK Takeda Pharmaceutical	$17.87 +0.0%	$18.06	$12.99 ▼ $19.10	$57.23B	-0.07	2.23 million shs	2.05 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	-5.70%	-9.84%	-9.84%	-16.17%	+46.32%
CHGCY Chugai Pharmaceutical	-1.23%	-7.95%	-10.01%	-17.29%	-16.32%
MKKGY Merck KGaA	-3.18%	-1.68%	-6.84%	-10.76%	+6.24%
TAK Takeda Pharmaceutical	-1.79%	-3.91%	-1.95%	+6.81%	+21.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	3.13	Buy	N/A	N/A
CHGCY Chugai Pharmaceutical	2.60	Moderate Buy	N/A	N/A
MKKGY Merck KGaA	2.00	Hold	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MKKGY, CHGCY, TAK, and BAYRY Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/11/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
9/2/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/1/2026	CHGCY Chugai Pharmaceutical	Nomura Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/20/2026	MKKGY Merck KGaA	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	MKKGY Merck KGaA	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2026	CHGCY Chugai Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/4/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/22/2026	MKKGY Merck KGaA	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/10/2026	BAYRY Bayer Aktiengesellschaft	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/6/2026	MKKGY Merck KGaA	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$51.55B	0.96	$2.04 per share	6.19	$7.50 per share	1.69
CHGCY Chugai Pharmaceutical	$8.41B	7.46	$0.92 per share	20.64	$4.12 per share	4.63
MKKGY Merck KGaA	$23.87B	0.84	$8.53 per share	3.62	$50.18 per share	0.62
TAK Takeda Pharmaceutical	$28.32B	2.02	$3.05 per share	5.86	$15.41 per share	1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$4.10B	-$0.51	N/A	9.43	2.03	-3.80%	16.77%	4.53%	11/3/2026 (Estimated)
CHGCY Chugai Pharmaceutical	$2.91B	$0.92	20.74	15.51	N/A	35.09%	23.76%	19.92%	10/23/2026 (Estimated)
MKKGY Merck KGaA	$2.95B	$1.94	15.91	15.36	2.94	11.20%	8.10%	4.58%	11/12/2026 (Estimated)
TAK Takeda Pharmaceutical	-$1.01B	$0.34	52.55	12.95	N/A	3.80%	10.95%	5.34%	10/29/2026 (Estimated)

Latest MKKGY, CHGCY, TAK, and BAYRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q2 2027	TAK Takeda Pharmaceutical	$0.1478	N/A	N/A	N/A	$7.31 billion	N/A
8/4/2026	Q2 2026	BAYRY Bayer Aktiengesellschaft	$0.23	$0.29	+$0.06	$0.07	$12.31 billion	$12.53 billion
7/30/2026	Q1 2027	TAK Takeda Pharmaceutical	$0.41	$0.95	+$0.54	$0.22	$7.13 billion	$7.50 billion
7/24/2026	Q2 2026	CHGCY Chugai Pharmaceutical	N/A	$0.22	N/A	$0.22	$2.38 billion	$2.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.16%	N/A	N/A	N/A
CHGCY Chugai Pharmaceutical	$0.25	1.31%	N/A	27.17%	N/A
MKKGY Merck KGaA	$0.35	1.13%	N/A	18.04%	N/A
TAK Takeda Pharmaceutical	$0.48	2.69%	-6.89%	141.18%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.05	1.04	0.67
CHGCY Chugai Pharmaceutical	N/A	4.35	3.54
MKKGY Merck KGaA	0.37	1.69	1.09
TAK Takeda Pharmaceutical	0.58	1.14	0.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
CHGCY Chugai Pharmaceutical	0.01%
MKKGY Merck KGaA	0.10%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
CHGCY Chugai Pharmaceutical	N/A
MKKGY Merck KGaA	N/A
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	88,078	3.93 billion	N/A	Not Optionable
CHGCY Chugai Pharmaceutical	7,872	3.29 billion	N/A	Not Optionable
MKKGY Merck KGaA	62,461	646.21 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,000	3.20 billion	3.20 billion	Optionable

MKKGY, CHGCY, TAK, and BAYRY Headlines

Recent News About These Companies

Reviewing Takeda Pharmaceutical (NYSE:TAK) and RYTHM (NASDAQ:RYM)

October 2 at 5:46 AM | americanbankingnews.com

Alpha Cognition (NASDAQ:ACOG) & Takeda Pharmaceutical (NYSE:TAK) Critical Contrast

October 2 at 4:45 AM | americanbankingnews.com

Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run

October 1 at 6:29 PM | finance.yahoo.com

Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal

October 1 at 1:28 PM | tmcnet.com

Takeda Pharmaceutical: Over 1 Trillion Yen in Core Operating Profit but 152.1 Billion Yen Net Loss; 2027 Determined by US Jury Verdict and 3 New Drugs

October 1 at 1:28 PM | note.comN

Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative

October 1 at 1:28 PM | finance.yahoo.com

Contrasting ProPhase Labs (NASDAQ:PRPH) and Takeda Pharmaceutical (NYSE:TAK)

October 1 at 4:46 AM | americanbankingnews.com

Takeda’s zasocitinib raises bar for oral psoriasis drugs

September 30 at 10:26 PM | bioworld.comB

Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data

September 30 at 10:26 PM | finance.yahoo.com

Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial

September 30 at 7:24 AM | rttnews.com

Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial

September 30 at 7:24 AM | rttnews.com

Takeda Pharmaceutical Company Limited Announces New Phase 3 Head-To-Head Results for Zasocitinib

September 30 at 7:24 AM | marketscreener.comM

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

September 30 at 1:00 AM | businesswire.com

Cronos Group (NASDAQ:CRON) vs. Takeda Pharmaceutical (NYSE:TAK) Critical Survey

September 29 at 4:59 AM | americanbankingnews.com

Ardelyx (NASDAQ:ARDX) vs. Takeda Pharmaceutical (NYSE:TAK) Critical Survey

September 25, 2026 | americanbankingnews.com

Roche proposes former Takeda CEO for board seat

September 23, 2026 | reuters.com

Takeda Pharmaceutical Company Limited Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research Led by Phase 3 Arcotatug Tavatecan Data At Esmo 2026

September 22, 2026 | marketscreener.comM

Dr Reddy’s partners with Takeda to launch India’s first dengue vaccine

September 19, 2026 | msn.com

Dr. Reddy’s to Roll Out Takeda’s Dengue Jab in India Next Year

September 18, 2026 | bloomberg.com

India's first dengue vaccine is coming: Dr Reddy's ties up with Japan's Takeda

September 18, 2026 | msn.com

Takeda Pharmaceutical (NYSE:TAK) Insider Sells 34,535 Shares of Stock

September 15, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MKKGY, CHGCY, TAK, and BAYRY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$12.64 -0.09 (-0.71%)

As of 03:59 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Chugai Pharmaceutical OTCMKTS:CHGCY

$19.08 -0.25 (-1.29%)

As of 04:00 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Merck KGaA OTCMKTS:MKKGY

$30.87 +0.76 (+2.52%)

As of 03:58 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Takeda Pharmaceutical NYSE:TAK

$17.87 +0.01 (+0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$18.14 +0.27 (+1.49%)

As of 07:30 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MKKGY, CHGCY, TAK, and BAYRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MKKGY, CHGCY, TAK, and BAYRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MKKGY, CHGCY, TAK, and BAYRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MKKGY, CHGCY, TAK, and BAYRY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Chugai Pharmaceutical OTCMKTS:CHGCY

Merck KGaA OTCMKTS:MKKGY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MKKGY, CHGCY, TAK, and BAYRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MKKGY, CHGCY, TAK, and BAYRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MKKGY, CHGCY, TAK, and BAYRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MKKGY, CHGCY, TAK, and BAYRY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Chugai Pharmaceutical OTCMKTS:CHGCY

Merck KGaA OTCMKTS:MKKGY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools